Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Operations (2016 - 2026)

Cytosorbents filings provide 15 years of Cash from Operations readings, the most recent being 4825000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 106.11% to 4825000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 12377000.0, a 14.22% increase, with the full-year FY2025 number at 12377000.0, up 14.22% from a year prior.
  • Cash from Operations hit 4825000.0 in Q4 2025 for Cytosorbents, down from 2577000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1510045.0 in Q2 2025 to a low of 8119170.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 4809620.5 (2024), compared with a mean of 4535000.85.
  • Biggest five-year swings in Cash from Operations: plummeted 419.15% in 2021 and later soared 68.5% in 2025.
  • Cytosorbents' Cash from Operations stood at 5491599.0 in 2021, then grew by 2.75% to 5340327.0 in 2022, then fell by 19.98% to 6407411.0 in 2023, then surged by 63.46% to 2341000.0 in 2024, then tumbled by 106.11% to 4825000.0 in 2025.
  • The last three reported values for Cash from Operations were 4825000.0 (Q4 2025), 2577000.0 (Q3 2025), and 1510045.0 (Q2 2025) per Business Quant data.